Gary Jay Sternberg
Chief Tech/Sci/R&D Officer chez AERIE PHARMACEUTICALS, INC.
Profil
Gary Jay Sternberg is the founder of Stargazer Pharmaceuticals, Inc. He currently holds the position of Chief Executive Officer at RainBio, Inc. since 2021 and Chief Medical Officer at Aerie Pharmaceuticals, Inc. since 2022.
Previously, he served as Chief Executive Officer at Tisbury Pharmaceuticals, Inc. and held the position of Director-Sales at Fovea Pharmaceuticals SA from 2006 to 2009.
He also worked as Group Medical Director & Head-Medical Affairs at GeneTech, Inc. Additionally, he served as Chief Business Officer at Sesen Bio, Inc. from 2014 to 2016.
Dr. Sternberg obtained an MBA from The University of Chicago and a doctorate from The State University of New York.
Postes actifs de Gary Jay Sternberg
| Sociétés | Poste | Début |
|---|---|---|
| AERIE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/03/2022 |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Founder | - |
RainBio, Inc.
 RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022. | Chief Executive Officer | 12/10/2021 |
Anciens postes connus de Gary Jay Sternberg
| Sociétés | Poste | Fin |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2016 |
GeneTech, Inc.
 GeneTech, Inc. Medical/Nursing ServicesHealth Services GeneTech, Inc. engages in fetal deoxyribonucleic acid (DNA) testing and clinical services. The company was founded on October 5, 2010 and is headquartered in Tokyo, Japan. | Chief Tech/Sci/R&D Officer | - |
Tisbury Pharmaceuticals, Inc.
 Tisbury Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Tisbury Pharmaceuticals Ltd. develops and markets groundbreaking therapy to treat primary open angle glaucoma. It focused on the discovery, development, and commercialization of groundbreaking therapy to treat primary open angle glaucoma. The company was founded by Andrew L. Salzman and is headquartered in Beverly, MA. | Chief Executive Officer | - |
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Corporate Officer/Principal | - |
Formation de Gary Jay Sternberg
| The University of Chicago | Masters Business Admin |
| The State University of New York | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
GeneTech, Inc.
GeneTech, Inc. Medical/Nursing ServicesHealth Services GeneTech, Inc. engages in fetal deoxyribonucleic acid (DNA) testing and clinical services. The company was founded on October 5, 2010 and is headquartered in Tokyo, Japan. | Health Services |
Tisbury Pharmaceuticals, Inc.
Tisbury Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Tisbury Pharmaceuticals Ltd. develops and markets groundbreaking therapy to treat primary open angle glaucoma. It focused on the discovery, development, and commercialization of groundbreaking therapy to treat primary open angle glaucoma. The company was founded by Andrew L. Salzman and is headquartered in Beverly, MA. | Health Technology |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Health Technology |
RainBio, Inc.
RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022. | Health Technology |
